Oryzon Genomics S.A.
A clinical-stage biopharma developing epigenetic therapies for cancer and CNS disorders.
ORY | MC
Overview
Corporate Details
- ISIN(s):
- ES0167733015
- LEI:
- 95980063R15RDF29DK13
- Country:
- Spain
- Address:
- Sant Ferran 74, 08940 Cornellà de Llobregat
- Website:
- https://www.oryzon.com/en
- Sector:
- Manufacturing
Description
Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-07-31 07:17 |
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
|
Spanish | 245.3 KB | ||
| 2020-06-26 21:32 |
Otorgamiento de la escritura de aumento de capital
|
Spanish | 65.8 KB | ||
| 2020-06-25 07:59 |
La compañía anuncia una ampliación de capital mediante una colocación privada
|
Spanish | 1.4 MB | ||
| 2020-06-12 08:34 |
ORYZON presenta datos positivos de eficacia de iadademstat de su ensayo clínico…
|
Spanish | 335.1 KB | ||
| 2020-05-11 19:11 |
ORYZON remite nota de prensa en relación a la composición de su Consejo de Admi…
|
Spanish | 282.2 KB | ||
| 2020-04-24 12:58 |
El fármaco VAFIDEMSTAT de Oryzon Genomics S.A. recibe la aprobación para llevar…
|
Spanish | 636.1 KB | ||
| 2020-04-23 00:00 |
Motivo de la notificación: Persona con Responsabilidad de Dirección
|
Spanish | 91.4 KB | ||
| 2020-04-17 18:24 |
ORYZON remite nota de prensa relativa a los planes de contingencia implementado…
|
Spanish | 432.6 KB | ||
| 2020-04-03 07:32 |
ORYZON presenta datos preliminares de eficacia de vafidemstat de sus dos ensayo…
|
Spanish | 510.7 KB | ||
| 2020-02-25 07:57 |
ORYZON remite nota de prensa en relación con un cambio en su Consejo de Adminis…
|
Spanish | 602.5 KB | ||
| 2020-02-24 08:11 |
Oryzon remite nota de prensa sobre resultados del ejercicio 2019
|
Spanish | 745.3 KB | ||
| 2020-02-24 00:00 |
Corporate Governance Report - Oryzon Genomics S.A.
|
Spanish | 163.2 KB | ||
| 2020-02-24 00:00 | Spanish | 2.7 MB | |||
| 2019-02-15 00:00 |
Corporate Governance Report - Oryzon Genomics S.A.
|
Spanish | 166.4 KB | ||
| 2019-02-15 00:00 | Spanish | 2.3 MB |
Automate Your Workflow. Get a real-time feed of all Oryzon Genomics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oryzon Genomics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oryzon Genomics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
